Overview
UCB is a global biopharmaceutical company focused on neurology and immunology, developing treatments for epilepsy, rheumatoid arthritis, and rare neurological disorders. Key products include CIMZIA® for inflammatory diseases, VIMPAT® and KEPPRA® for epilepsy, and emerging therapies like BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO®, and ZILBRYSQ®. The company invests about a quarter of its revenue in R&D, with operations in nearly 40 countries and headquarters in Brussels, Belgium.
Frequently asked questions
- What are UCB's main therapeutic areas and key products?
- UCB focuses on neurology (epilepsy, rare disorders) and immunology (rheumatoid arthritis, psoriasis). Top products include CIMZIA®, VIMPAT®, KEPPRA®, BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO®, and ZILBRYSQ®.
- What is UCB's R&D focus and capabilities?
- UCB invests ~25% of revenue in cutting-edge research for unmet needs in neurology and immunology, with a robust pipeline including brain-penetrant small molecules and exploration of gene therapy.
- Where does UCB operate geographically?
- UCB has ~7,500 employees in nearly 40 countries, global HQ in Brussels, Belgium, and U.S. HQ in Atlanta, Georgia.